{"id":"factor-ix-recovery","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Inhibitor development (alloimmunization)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Factor IX is a vitamin K-dependent serine protease essential for the intrinsic pathway of blood coagulation. Factor IX recovery assays measure the in vivo hemostatic activity of administered Factor IX products, typically expressed as a percentage of expected activity based on the dose given. This metric is used to assess the efficacy and bioavailability of Factor IX replacement therapies in patients with Factor IX deficiency (hemophilia B).","oneSentence":"Factor IX recovery refers to the measurement of how much functional Factor IX (a blood clotting protein) is present in the bloodstream after administration of a Factor IX replacement product.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:46:14.728Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hemophilia B (Factor IX deficiency)"},{"name":"Prevention and treatment of bleeding episodes in Factor IX-deficient patients"}]},"trialDetails":[{"nctId":"NCT03855280","phase":"PHASE3","title":"Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B","status":"COMPLETED","sponsor":"Medexus Pharma, Inc.","startDate":"2020-01-16","conditions":"Hemophilia B","enrollment":21},{"nctId":"NCT02234310","phase":"PHASE3","title":"Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ, a Sanofi company","startDate":"2014-11-13","conditions":"Hemophilia B","enrollment":33},{"nctId":"NCT01425723","phase":"PHASE3","title":"Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2011-12-08","conditions":"Severe Hemophilia B","enrollment":120},{"nctId":"NCT00749476","phase":"PHASE4","title":"Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-04","conditions":"Hemophilia B","enrollment":1},{"nctId":"NCT00866606","phase":"PHASE3","title":"Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-02","conditions":"Hemophilia B","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Factor IX recovery","genericName":"Factor IX recovery","companyName":"Wyeth is now a wholly owned subsidiary of Pfizer","companyId":"wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer","modality":"Biologic","firstApprovalDate":"","aiSummary":"Factor IX recovery is a treatment for Hemophilia B, a condition where the body lacks or does not produce enough coagulation factor IX. This treatment involves administering an exogenous protein, specifically a recombinant form of coagulation factor IX, to replace the deficient or missing protein and facilitate blood clotting.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}